Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. SRTA
SRTA logo

SRTA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
4.590
Open
4.500
VWAP
4.50
Vol
895.83K
Mkt Cap
394.93M
Low
4.350
Amount
4.03M
EV/EBITDA(TTM)
--
Total Shares
86.99M
EV
333.70M
EV/OCF(TTM)
--
P/S(TTM)
1.89
Strata Critical Medical, Inc. provides time-critical logistics solutions and specialized medical services to healthcare providers across the United States, expanding its portfolio of services through acquisition and organic growth. The Company focuses on the contractual and macro-non-correlated marketplaces for organ logistics and other medical services. Its subsidiary, Trinity Medical Solutions (Trinity), is engaged in the air and ground transportation of human organs for transplant, leveraging its asset-light platform to deliver logistics solutions to its customers across the United States. Trinity provides Organ Placement Services (TOPS) and Logistics Solutions for Transplant Centers and organ procurement organizations (OPOS). The Company also offers a full-service organ transplant service provider offering surgical recovery, NRP services, air and ground logistics and organ placement services.
Show More

Events Timeline

(ET)
2026-03-03
07:10:00
Raises EBITDA Outlook to $29M-$33M
select
2026-03-03
07:10:00
Will Heyburn: Company Aims for 30% Annual EBITDA Growth
select
2026-02-05 (ET)
2026-02-05
08:50:00
Strata Critical Medical Enters $30M Credit Agreement with JPMorgan
select
2025-11-10 (ET)
2025-11-10
07:15:25
Strata Critical Adjusts FY25 Revenue Forecast to $185M-$195M, Up from $180M-$190M
select
2025-11-10
07:14:51
Strata Critical Medical Reports Q3 Earnings Per Share of 70 Cents Compared to (3 Cents) Last Year
select
2025-09-16 (ET)
2025-09-16
08:38:37
Strata finalizes purchase of Keystone Perfusion
select

News

seekingalpha
9.5
03-03seekingalpha
Strata Critical Medical Reports Strong Q4 2025 Earnings
  • Organic Growth Exceeds Expectations: Strata Critical Medical achieved a remarkable 35% organic growth in Q4 2025, with revenue reaching $66.8 million, surpassing expectations and demonstrating strong performance post-Keystone acquisition, thereby solidifying its market position in organ transportation.
  • 2026 Guidance Raised: Management raised the 2026 revenue guidance to a range of $260 million to $275 million, with adjusted EBITDA guidance increased to $29 million to $33 million, reflecting ongoing customer growth and robust market demand, indicating enhanced future profitability.
  • Acquisition and Asset Strategy: The company plans to add two dedicated aircraft in 2026 to support expansion into new markets while securing a $30 million asset-based credit facility to fund future acquisitions, showcasing its proactive approach in M&A activities.
  • Regulatory Policy Benefits: Management highlighted that regulatory policies aimed at incentivizing more DCD donors are a clear positive for the company, leveraging its expertise in organ recovery and transportation to potentially increase market share and business growth opportunities.
Benzinga
9.5
03-03Benzinga
Ingram Micro Reports Strong Quarterly Earnings, Shares Surge
  • Earnings Beat Expectations: Ingram Micro reported a quarterly adjusted EPS of 96 cents, surpassing the analyst consensus estimate of 88 cents, indicating strong profitability and boosting investor confidence.
  • Sales Missed Targets: Despite the positive EPS, the company's quarterly sales were $14.878 billion, falling short of the analyst consensus of $14.073 billion, reflecting challenges in market demand that could impact future growth.
  • Stock Price Surge: Following the earnings report, Ingram Micro's shares jumped 11.8% to $23.87, demonstrating a positive market reaction to the company's profitability, potentially attracting more investor interest.
  • Overall Market Decline: While Ingram Micro performed well, the broader market saw a decline, with the Dow Jones index dropping over 1,100 points on Tuesday, indicating volatility in market sentiment that could negatively affect other stocks.
NASDAQ.COM
9.5
03-03NASDAQ.COM
Strata Critical Medical Reports 83.5% Revenue Growth in Q4
  • Significant Revenue Growth: Strata Critical Medical reported total revenue of $66.79 million in Q4, an 83.5% increase year-over-year, indicating strong market demand in the organ transport sector and potential for further business expansion.
  • Surge in Adjusted EBITDA: The company's adjusted EBITDA skyrocketed from $1.08 million last year to $6.96 million, reflecting a 547% increase, which demonstrates substantial improvements in operational efficiency and profitability, thereby boosting investor confidence.
  • Optimistic 2026 Outlook: The firm raised its revenue guidance for 2026 to between $260 million and $275 million, representing a growth of approximately 32% to 39% from 2025, showcasing management's strong confidence in future growth potential.
  • Successful Acquisition Integration: Following the acquisition of Keystone, over 40% of the logistics revenue growth in Q4 came from Keystone's legacy customers, validating the success of the integration strategy and further solidifying the company's market position.
NASDAQ.COM
2.0
03-03NASDAQ.COM
Strata Critical Medical (SRTA) Earnings Call
seekingalpha
9.5
03-03seekingalpha
Strata Critical Medical Reports 83.5% Revenue Growth in Q4
  • Significant Revenue Growth: Strata Critical Medical reported fourth-quarter revenue of $66.8 million, reflecting an impressive 83.5% year-over-year increase, driven by strong performance in its core logistics segment and contributions from the Keystone acquisition, indicating robust growth potential in the organ logistics market.
  • Improved Profitability: The company achieved a 90% increase in gross profit to $14.4 million in Q4, with gross margin rising from 20.8% to 21.6%, demonstrating significant progress in cost control and operational efficiency, thereby enhancing the sustainability of future profitability.
  • 2026 Outlook Raised: Strata raised its 2026 revenue guidance to a range of $260 million to $275 million, up from previous guidance of $255 million to $270 million, reflecting confidence in future growth, with expected free cash flow of $15 million to $22 million.
  • Increased Acquisition Opportunities: Executives highlighted ongoing efforts to pursue multiple acquisition opportunities, aiming for an average annualized adjusted EBITDA growth rate of at least 30% in the coming years, indicating a strategic focus on consolidating its position in the evolving transplant logistics market.
seekingalpha
9.5
03-03seekingalpha
Blade Air Mobility Reports 83.5% Revenue Growth in Q4
  • Significant Revenue Growth: Blade Air Mobility reported Q4 2025 revenue of $66.79 million, an impressive 83.5% year-over-year increase, surpassing market expectations by $6.44 million, indicating strong performance and rising demand in the logistics sector.
  • Logistics Revenue and Gross Profit Increase: The logistics revenue and gross profit grew by 35.3% and 39.5% respectively in Q4, demonstrating Strata's robust organic growth momentum and solidifying its competitive position in the industry.
  • Reduced Net Loss: The net loss from continuing operations decreased by $2.0 million year-over-year to $(5.4) million, compared to $(7.4) million in the prior year, reflecting improvements in cost control and operational efficiency.
  • Upgraded 2026 Financial Outlook: Blade Air Mobility raised its 2026 revenue and adjusted EBITDA guidance, now expecting revenue between $260 million and $275 million and adjusted EBITDA between $29 million and $33 million, showcasing confidence in future growth prospects.
Wall Street analysts forecast SRTA stock price to rise
2 Analyst Rating
Wall Street analysts forecast SRTA stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
8.00
Averages
9.63
High
11.25
Current: 0.000
sliders
Low
8.00
Averages
9.63
High
11.25
Lake Street
Buy
maintain
AI Analysis
2025-09-17
Reason
Lake Street
Price Target
AI Analysis
2025-09-17
maintain
Buy
Reason
Lake Street raised the firm's price target on Strata Critical Medical to $7.25 from $6.50 and keeps a Buy rating on the shares. The firm is \"highly supportive\" of the announced acquisition of Keystone Perfusion Services for $124M pre-earnout, as it successfully addresses a concern of how post-Passenger Strata could truly deploy its massive $235M pro forma cash position in a material way via M&A, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Strata Critical Medical Inc (SRTA.O) is 7.70, compared to its 5-year average forward P/E of -16.78. For a more detailed relative valuation and DCF analysis to assess Strata Critical Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-16.78
Current PE
7.70
Overvalued PE
7.66
Undervalued PE
-41.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
8.86
Current EV/EBITDA
5.64
Overvalued EV/EBITDA
12.70
Undervalued EV/EBITDA
5.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.29
Current PS
1.07
Overvalued PS
1.58
Undervalued PS
1.00

Financials

AI Analysis
Annual
Quarterly

Whales Holding SRTA

T
Third Point LLC
Holding
SRTA
+0.65%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Strata Critical Medical Inc (SRTA) stock price today?

The current price of SRTA is 4.57 USD — it has increased 0.66

What is Strata Critical Medical Inc (SRTA)'s business?

Strata Critical Medical, Inc. provides time-critical logistics solutions and specialized medical services to healthcare providers across the United States, expanding its portfolio of services through acquisition and organic growth. The Company focuses on the contractual and macro-non-correlated marketplaces for organ logistics and other medical services. Its subsidiary, Trinity Medical Solutions (Trinity), is engaged in the air and ground transportation of human organs for transplant, leveraging its asset-light platform to deliver logistics solutions to its customers across the United States. Trinity provides Organ Placement Services (TOPS) and Logistics Solutions for Transplant Centers and organ procurement organizations (OPOS). The Company also offers a full-service organ transplant service provider offering surgical recovery, NRP services, air and ground logistics and organ placement services.

What is the price predicton of SRTA Stock?

Wall Street analysts forecast SRTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRTA is9.63 USD with a low forecast of 8.00 USD and a high forecast of 11.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Strata Critical Medical Inc (SRTA)'s revenue for the last quarter?

Strata Critical Medical Inc revenue for the last quarter amounts to 66.79M USD, increased 22.87

What is Strata Critical Medical Inc (SRTA)'s earnings per share (EPS) for the last quarter?

Strata Critical Medical Inc. EPS for the last quarter amounts to -0.10 USD, decreased -16.67

How many employees does Strata Critical Medical Inc (SRTA). have?

Strata Critical Medical Inc (SRTA) has 310 emplpoyees as of March 09 2026.

What is Strata Critical Medical Inc (SRTA) market cap?

Today SRTA has the market capitalization of 394.93M USD.